Padmanee Sharma
Medical Oncology · Houston, TXNPI 1154427078
Payments from drug & device makers
What this record shows
This record is dominated by education: $5,605 of the $7,663 with a category attached, or 73.1%. E.r. Squibb & Sons, L.L.C. accounts for 84.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $5,605 and has fallen 99.6% since, to $20 in 2025.
Across 15 payments — averaging $510.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$6K
- Cue Health Inc.$867
- Johnson & Johnson$118
- Janssen Research & Development, LLC$89
- Regeneron$89
- Exelixis Inc.$20
Across 63 payments — averaging $203,401 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$4.5M
- Astellas Pharma Inc$3.1M
- E.r. Squibb & Sons, L.L.C.$2.4M
- Johnson & Johnson$1.4M
- Janssen Research & Development, LLC$900K
- AstraZeneca$324K
- plus $191K from 1 others
What the payments were for
- Travel & lodging$6669%
- Food & beverage$5267%
- Education$5,60573%
- Gifts$86711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 8 | $6,482 |
| Cue Health Inc. | 1 | $867 |
| Johnson & Johnson | 2 | $118 |
| Janssen Research & Development, LLC | 2 | $89 |
| Regeneron | 1 | $89 |
| Exelixis Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$6,306
- Cue Health Monitoring System$867
How this compares
$7,663 in reported general payments places this provider in the 55th percentile of 495 medical oncology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 18 | $438,012 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $20 | $438,01218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Houston
- Roy HerbstHouston$1.9M
- Maen AbdelrahimHouston$999K
- John HeymachHouston$726K
- Putao CenHouston$720K
- Hagop KantarjianHouston$559K
- Ricardo AlvarezHouston$553K
- Eleni EfstathiouHouston$519K
- Srdan VerstovsekHouston$464K
- Guillermo Garcia-ManeroHouston$454K
- Jason WestinHouston$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.